New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

Prespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

The survey of 21,753 people, including nearly 3,500 cancer survivors, found alarmingly low levels of trust in experts, with ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

The world’s largest meeting on cancer research has brought promising updates on treatment and prevention for colorectal ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

A first-of-its-kind experiment shows a three-year exercise program improved survival in colon cancer patients.

Five early-career Fred Hutch/UW researchers received prestigious Young Investigator Awards from Conquer Cancer, the ASCO Foundation during this year's annual meeting of the American Society of ...

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

New data support the role of structured exercise and low inflammatory diets to improve survival and quality of life following ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.